Compare LNTH & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNTH | PTCT |
|---|---|---|
| Founded | 1956 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.3B |
| IPO Year | 2015 | 2013 |
| Metric | LNTH | PTCT |
|---|---|---|
| Price | $66.12 | $75.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 17 |
| Target Price | ★ $77.33 | $73.76 |
| AVG Volume (30 Days) | 1.0M | ★ 2.2M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.39 | ★ 8.94 |
| Revenue | $1,525,933,000.00 | ★ $1,779,150,000.00 |
| Revenue This Year | $0.01 | $128.32 |
| Revenue Next Year | $1.24 | N/A |
| P/E Ratio | $27.84 | ★ $8.46 |
| Revenue Growth | 1.95 | ★ 97.54 |
| 52 Week Low | $47.25 | $35.95 |
| 52 Week High | $111.29 | $87.50 |
| Indicator | LNTH | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 72.55 | 50.79 |
| Support Level | $60.15 | $73.09 |
| Resistance Level | $64.40 | $78.77 |
| Average True Range (ATR) | 2.09 | 3.15 |
| MACD | 0.66 | -1.02 |
| Stochastic Oscillator | 94.44 | 18.45 |
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.